BBIO
VENTE TOTALE: 200 736 titres (~16 762 110,01 $ US)
- Insiders
- Kumar Neil, Ellis Andrea, Cook Jennifer E.
- Total bought
- —
- Total sold
- $16,762,110
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-22
BBIO presents a compelling near-term event-driven opportunity driven by Attruby's strong commercial ramp (sales tripling YoY) and a reaffirmed $1B+ 2026 revenue guidance, supported by a moderately confident catalyst…
The first sentence of the analysis written for BBIO on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 94.4% | 98.3% | 73.7% | 95.6% | 95.5% | |
| Ebit Margin | -135.8% | -199.6% | -6148.1% | -520.6% | -774.1% | |
| Ebitda Margin | -134.0% | -196.9% | -6078.3% | -511.9% | -765.7% | |
| Operating Profit Margin | -113.3% | -267.2% | -6528.8% | -659.6% | -827.1% | |
| Pretax Profit Margin | -146.4% | -244.3% | -7021.9% | -624.2% | -841.2% | |
| Continuous Operations Profit Margin | -146.5% | -244.9% | -7021.9% | -624.2% | -841.2% | |
| Net Profit Margin | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | |
| Bottom Line Profit Margin | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | |
| Current Ratio | 2.617 | 4.668 | 3.320 | 4.520 | 6.581 | |
| Quick Ratio | 2.524 | 4.668 | 3.320 | 4.520 | 6.581 | |
| Solvency Ratio | -0.239 | -0.223 | -0.337 | -0.254 | -0.296 | |
| Cash Ratio | 1.980 | 4.411 | 2.613 | 3.102 | 2.915 | |
| Price To Earnings Ratio | -20.182 | -9.528 | -10.220 | -2.275 | -4.277 | |
| Price To Earnings Growth Ratio | -0.639 | 0.352 | -0.571 | 0.161 | 0.877 | |
| Forward Price To Earnings Growth Ratio | -0.639 | 0.352 | -0.571 | 0.161 | 0.877 | |
| Price To Earnings Diluted Ratio | -20.182 | -9.528 | -10.220 | -2.275 | -4.277 | |
| Price To Earnings Diluted Growth Ratio | -0.639 | 0.352 | -0.571 | 0.161 | 0.877 | |
| Price To Book Ratio | -7.265 | -3.478 | -4.853 | -0.896 | -2.766 | |
| Price To Sales Ratio | 30.049 | 23.010 | 706.427 | 14.472 | 34.538 | |
| Price To Free Cash Flow Ratio | -33.751 | -9.788 | -12.423 | -2.639 | -4.409 | |
| Price To Operating Cash Flow Ratio | -33.834 | -9.805 | -12.453 | -2.679 | -4.836 | |
| Debt To Assets Ratio | 2.915 | 1.882 | 3.184 | 2.766 | 1.704 | |
| Debt To Equity Ratio | -1.314 | -1.179 | -1.285 | -1.374 | -1.983 | |
| Debt To Capital Ratio | 4.184 | 6.588 | 4.512 | 3.675 | 2.017 | |
| Long Term Debt To Capital Ratio | 4.291 | 6.791 | 4.636 | 3.770 | 2.044 | |
| Financial Leverage Ratio | -0.451 | -0.626 | -0.403 | -0.497 | -1.164 | |
| Working Capital Turnover Ratio | 0.973 | 0.493 | 0.024 | 0.131 | 0.107 | |
| Operating Cash Flow Ratio | -1.548 | -3.373 | -3.669 | -3.455 | -3.687 | |
| Operating Cash Flow Sales Ratio | -0.888 | -2.347 | -56.726 | -5.403 | -7.142 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.002 | 1.002 | 1.015 | 1.097 | |
| Debt Service Coverage Ratio | -9.550 | -4.411 | -6.956 | -4.941 | -11.412 | |
| Interest Coverage Ratio | -10.717 | -5.972 | -7.472 | -6.368 | -12.327 | |
| Short Term Operating Cash Flow Coverage Ratio | -25.608 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.163 | -0.301 | -0.303 | -0.243 | -0.288 | |
| Capital Expenditure Coverage Ratio | -406.481 | -558.120 | -404.074 | -66.365 | -10.321 | |
| Dividend Paid And Capex Coverage Ratio | -406.481 | -558.120 | -404.074 | -66.365 | -10.321 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -25.629 | -14.091 | -14.034 | -6.216 | -7.006 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 94.4% | ▼-3.9% | ▲2.9% |
| Ebit Margin | -135.8% | ▲63.8% | ▲1419.8% |
| Ebitda Margin | -134.0% | ▲62.8% | ▲1403.3% |
| Operating Profit Margin | -113.3% | ▲153.9% | ▲1565.9% |
| Pretax Profit Margin | -146.4% | ▲98.0% | ▲1629.2% |
| Continuous Operations Profit Margin | -146.5% | ▲98.4% | ▲1629.2% |
| Net Profit Margin | -145.3% | ▲96.2% | ▲1600.2% |
| Bottom Line Profit Margin | -145.3% | ▲96.2% | ▲1600.2% |
| Current Ratio | 2.617 | ▼-2.050 | ▼-1.724 |
| Quick Ratio | 2.524 | ▼-2.143 | ▼-1.798 |
| Solvency Ratio | -0.239 | ▼-0.016 | ▲0.031 |
| Cash Ratio | 1.980 | ▼-2.432 | ▼-1.025 |
| Price To Earnings Ratio | -20.182 | ▼-10.654 | ▼-10.886 |
| Price To Earnings Growth Ratio | -0.639 | ▼-0.991 | ▼-0.675 |
| Forward Price To Earnings Growth Ratio | -0.639 | ▼-0.991 | ▼-0.675 |
| Price To Earnings Diluted Ratio | -20.182 | ▼-10.654 | ▼-10.886 |
| Price To Earnings Diluted Growth Ratio | -0.639 | ▼-0.991 | ▼-0.675 |
| Price To Book Ratio | -7.265 | ▼-3.787 | ▼-3.413 |
| Price To Sales Ratio | 30.049 | ▲7.039 | ▼-131.651 |
| Price To Free Cash Flow Ratio | -33.751 | ▼-23.963 | ▼-21.149 |
| Price To Operating Cash Flow Ratio | -33.834 | ▼-24.028 | ▼-21.112 |
| Debt To Assets Ratio | 2.915 | ▲1.033 | ▲0.425 |
| Debt To Equity Ratio | -1.314 | ▼-0.135 | ▲0.113 |
| Debt To Capital Ratio | 4.184 | ▼-2.404 | ▼-0.011 |
| Long Term Debt To Capital Ratio | 4.291 | ▼-2.500 | ▼-0.015 |
| Financial Leverage Ratio | -0.451 | ▲0.175 | ▲0.177 |
| Working Capital Turnover Ratio | 0.973 | ▲0.480 | ▲0.627 |
| Operating Cash Flow Ratio | -1.548 | ▲1.824 | ▲1.598 |
| Operating Cash Flow Sales Ratio | -0.888 | ▲1.458 | ▲13.613 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▲0.001 | ▼-0.021 |
| Debt Service Coverage Ratio | -9.550 | ▼-5.139 | ▼-2.096 |
| Interest Coverage Ratio | -10.717 | ▼-4.745 | ▼-2.146 |
| Short Term Operating Cash Flow Coverage Ratio | -25.608 | ▼-25.608 | ▼-20.486 |
| Operating Cash Flow Coverage Ratio | -0.163 | ▲0.138 | ▲0.097 |
| Capital Expenditure Coverage Ratio | -406.481 | ▲151.639 | ▼-117.409 |
| Dividend Paid And Capex Coverage Ratio | -406.481 | ▲151.639 | ▼-117.409 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -25.629 | ▼-11.538 | ▼-12.234 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $15.09B | $5.11B | $6.57B | $1.12B | $2.41B | |
| Enterprise value | $17.25B | $6.16B | $7.94B | $2.47B | $3.74B | |
| EV / Sales | 34.35x | 27.74x | 853.04x | 31.82x | 53.65x | |
| EV / Op. cash flow | -38.67x | -11.82x | -15.04x | -5.89x | -7.51x | |
| EV / Free cash flow | -38.58x | -11.80x | -15.00x | -5.80x | -6.85x | |
| EV / EBITDA | -25.63x | -14.09x | -14.03x | -6.22x | -7.01x | |
| Net debt / EBITDA | -3.21x | -2.40x | -2.41x | -3.39x | -2.50x | |
| Current ratio | 2.62x | 4.67x | 3.32x | 4.52x | 6.58x | |
| Income quality | 0.61x | 0.96x | 0.82x | 0.87x | 0.85x | |
| Graham net-net | -$12 | -$9 | -$9 | -$9 | -$7 | |
| Tax burden | 99.2% | 98.8% | 98.5% | 99.3% | 95.9% | |
| Interest burden | 107.8% | 122.4% | 114.2% | 119.9% | 108.7% | |
| Working capital | $465.7M | $566.3M | $333.7M | $427.4M | $753.8M | |
| Invested capital | $507.3M | $603.0M | $379.9M | $481.4M | $844.7M | |
| Return on assets | -77.9% | -58.3% | -117.7% | -77.2% | -55.5% | |
| Operating ROA | -61.3% | -80.9% | -103.9% | -62.6% | -67.2% | |
| Return on tangible assets | -80.3% | -59.8% | -123.7% | -81.0% | -58.1% | |
| Return on equity | 35.1% | 36.5% | 47.5% | 38.4% | 64.6% | |
| Return on invested capital | -108.5% | -77.1% | -149.4% | -101.4% | -65.3% | |
| Return on capital employed | -87.8% | -77.5% | -150.9% | -102.1% | -65.7% | |
| Earnings yield | -4.8% | -10.5% | -9.8% | -42.8% | -23.4% | |
| Free cash flow yield | -3.0% | -10.2% | -8.0% | -37.9% | -22.7% | |
| Capex / Op. cash flow | -0.2% | -0.2% | -0.2% | -1.5% | -9.7% | |
| Capex / Depreciation | 18.4% | 15.4% | 20.1% | 93.4% | 825.7% | |
| Capex / Sales | 0.2% | 0.4% | 14.0% | 8.1% | 69.2% | |
| SG&A / Sales | 110.6% | 130.2% | 1618.7% | 184.4% | 275.7% | |
| R&D / Sales | 95.1% | 228.2% | 4898.5% | 514.5% | 646.9% | |
| Stock comp / Sales | 26.5% | 43.2% | 0.0% | 117.9% | 142.7% | |
| Intangibles / Total assets | 3.0% | 2.6% | 4.8% | 4.6% | 4.4% | |
| Days sales outstanding | 101d | 8d | 69d | 80d | 103d | |
| Days payables outstanding | 468d | 905d | 1590d | 1228d | 1393d | |
| Operating cycle | 447d | 8d | 69d | 80d | 103d | |
| Cash conversion cycle | -21d | -897d | -1521d | -1148d | -1290d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+195.5%EV / Sales ▲+23.8%EV / EBITDA ▼-81.9%EV / Op. cash flow ▼-26.854Earnings yield ▲+0.057
Profitability
Return on equity ▼-0.014Return on assets ▼-0.196Return on invested capital ▼-0.314Return on capital employed ▼-0.103Operating ROA ▲+0.196Income quality ▼-0.343Tax burden ▲+0.004
Efficiency
Days sales outstanding ▲+93.606Days payables outstanding ▼-437.555Operating cycle ▲+438.983Cash conversion cycle ▲+876.538Capex / Sales ▼-0.002R&D / Sales ▼-1.331
Balance-sheet strength
Current ratio ▼-2.050Net debt / EBITDA ▼-0.805Working capital ▼-100584000.000Invested capital ▼-95696000.000Intangibles / Total assets ▲+0.004
Change over 5 years
Valuation
Market cap ▲+526.6%EV / Sales ▼-36.0%EV / EBITDA ▼-265.8%EV / Op. cash flow ▼-31.163Earnings yield ▲+0.185
Profitability
Return on equity ▼-0.295Return on assets ▼-0.224Return on invested capital ▼-0.431Return on capital employed ▼-0.221Operating ROA ▲+0.058Income quality ▼-0.234Tax burden ▲+0.033
Efficiency
Days sales outstanding ▼-2.024Days payables outstanding ▼-925.257Operating cycle ▲+343.353Cash conversion cycle ▲+1268.610Capex / Sales ▼-0.690R&D / Sales ▼-5.518
Balance-sheet strength
Current ratio ▼-3.964Net debt / EBITDA ▼-0.712Working capital ▼-288081000.000Invested capital ▼-337396000.000Intangibles / Total assets ▼-0.014
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-19 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-22 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-08 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-14 BridgeBio Stock Has Soared 29% in Just 3 Months. Here''s Why Wall Street Thinks It Could Go Even Higher. Sales of BridgeBio''s cutting-edge heart drug nearly tripled year over year in the second quarter. The biotech also has other medications in late-stage development that are packed with potential.
- 2026-08-14 BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base - The transaction supports the evolution of the Company''s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the pricing of a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P.
- 2026-08-13 BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering.
- 2026-08-12 BridgeBio Pharma Q2 Earnings Call Highlights BridgeBio Pharma (NASDAQ: BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year. Chief Executive Officer Neil Kumar described the period as a transition point for the company, citing the commercial
- 2026-08-11 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio''s board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company''s common stock. One-fourth of the shares underlying each employee''s restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee''s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee''s continued employment with the Company or one of its subsidiaries on such vesting dates.
- 2026-08-11 BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge BBIO''s Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
- 2026-08-11 BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby''s U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO''s $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline investment.
- 2026-08-11 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
- 2026-08-10 BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
- 2026-08-10 BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.